Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Drug Name IMO-2125
Trade Name
Synonyms Tilsotolimod
Drug Descriptions

Tilsotolimod (IMO-2125) is an immunomodulatory oligonucleotide (IMO) that targets toll-like receptor 9 (TLR9), resulting in activation of anti-tumor immunity (PMID: 23207140, PMID: 29956749).

DrugClasses TLR9 Agonist 9
CAS Registry Number 2089768-67-0
NCIT ID C125080

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
ABBV-368 + Budigalimab + IMO-2125 + Nab-paclitaxel ABBV-368 Budigalimab IMO-2125 Nab-paclitaxel 0 1
ABBV-368 + IMO-2125 ABBV-368 IMO-2125 0 1
ABBV-368 + IMO-2125 + Nab-paclitaxel ABBV-368 IMO-2125 Nab-paclitaxel 0 1
IMO-2125 IMO-2125 0 2
IMO-2125 + Ipilimumab IMO-2125 Ipilimumab 0 2
IMO-2125 + Ipilimumab + Nivolumab IMO-2125 Ipilimumab Nivolumab 0 2
IMO-2125 + Nivolumab IMO-2125 Nivolumab 0 1
IMO-2125 + Pembrolizumab IMO-2125 Pembrolizumab 0 1


Additional content available in CKB BOOST